Abstract
We studied the administration method during a transition period from continuous intravenous (i.v.) infusion to oral administration of cyclosporin A (CsA). Thirty-two pediatric hematopoietic stem cell transplant (HSCT) recipients, between the ages of 8 months and 15.6 years (median 7.1 years) participated in this study. The pharmacokinetic properties of CsA was evaluated during the transition period from i.v. to oral CsA. The daily oral dose of CsA was three times higher than the i.v. dose. Oral dosing began immediately after the continuous infusion was discontinued. Whole-blood CsA concentrations were measured by a monoclonal fluorescence polarization immunoassay (FPIA). The mean±s.d. value of bioavailability (F), maximum concentration (Cmax), half-life (t1/2) of CsA were 43.1±14.4%, 1135.3±340.6 ng/ml and 3.1±1.2 h, respectively. Mean clearance (CL)±s.d. was 480.9±103.7, 414.9±137.1 and 320±51.8 ml/h/kg in patients <20, 20–40 and >40 kg of body weight, respectively. The CsA CL of younger children was significantly greater than for older children (P=0.044). CsA trough levels were maintained within the therapeutic range throughout the transition period. Therefore, our findings suggest that the immediate administration of an oral formulation, after discontinuation of the continuous infusion, would be practical and effective for routine clinical use.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Atkinson K . Cyclosporin in bone marrow transplantation. Bone Marrow Transplant 1987; 1: 265–270.
Storb R, Deeg HJ, Pepe M, Frederick A, Anasetti C, Beatty P et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729–1734.
Yau JC, LeMaistre CF, Zagars GK, William LA, Meneghetti CM, Luke DR et al. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplant 1990; 5: 269–272.
Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225–1230.
Simpson D . Drug therapy for acute graft-versus-host disease prophylaxis. J Hematother Stem Cell Res 2000; 9: 317–325.
Arai S, Vogelsang GB . Management of graft-versus-host disease. Blood Rev 2000; 14: 190–204.
Locatelli F, Uderzo C, Dini G, Zecca M, Arcese W, Messina C et al. Graft-versus-host disease in children: the AIEOP-BMT group experience with cyclosporin A. Bone Marrow Transplant 1993; 12: 627–633.
Peters C, Minkov M, Gadner H, Klingebiel T, Vossen J, Locatelli F et al. Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant 2000; 26: 405–411.
Shaw LM, Bowers L, Demers L, Freeman D, Moyer T, Sanghvi A et al. Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring. Clin Chem 1987; 33: 1269–1288.
Lindholm A, Henricsson S, Lind LM, Dahlqvist R . Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. Eur J Clin Pharmacol 1988; 34: 461–464.
Fahr A . Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24: 472–495.
Lindholm A . Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monitor 1991; 13: 465–477.
Atkinson K, Biggs JC, Britton K, Short R, Mrongovius R, Concannon A et al. Oral administration of cyclosporin A for recipients of allogeneic marrow transplants: implications of clinical gut dysfunction. Br J Hematol 1984; 56: 223–231.
Yee GC . Pharmacokinetic and pharmacodynamic studies of cyclosporine in bone marrow transplantation. Transplant Proc 1990; 22: 1327–1330.
Schultz KR, Nevill TJ, Balshaw RF, Toze CL, Corr T, Currie CJ et al. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. Bone Marrow Transplant 2000; 26: 545–551.
Yee GC, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ . Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 1986; 40: 438–443.
Cooney GF, Habucky K, Hoppu K . Cyclosporin pharmacokinetics in pediatric transplant recipients. Clin Pharmacokinet 1997; 32: 481–495.
Burckart G, Starzl T, Williams L, Sanghvi A, Gartner C, Venkataramanan JR et al. Cyclosporine monitoring and pharmacokinetics in pediatric liver transplant patients. Transplant Proc 1985; 17: 1172–1175.
Burckart GJ, Venkataramanan R, Ptachcinski RJ, Ptachcinski RJ, Starzl TE, Gartner JC et al. Cyclosporine absorption following orthotopic liver transplantation. J Clin Pharmacol 1986; 26: 647–651.
Dunn SP, Cooney GF, Kulinsky A, Falkenstein K, Pierson A, Elder CA et al. Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients. Transplantation 1995; 60: 1438–1442.
Neiberger R, Weiss R, Gomez M, Greifer I, Tellis VA, Matas AJ . Elimination kinetics of cyclosporine following oral administration to children with renal transplants. Transplant Proc 1987; 19: 1525.
Hoppu K, Koskimies O, Holmberg C, Hirvisalo EL . Pharmacokinetically determined cyclosporine dosage in young children. Pediatr Nephrol 1991; 5: 1–4.
Whitington PF, Emond JC, Whitington SH, Broelsch CE, Baker AL . Small bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med 1990; 322: 733–738.
Mochon M, Cooney G, Lum B, Caputo C, Dunn S, Goldsmith B et al. Pharmacokinetics of cyclosporine after renal transplant in children. J Clin Pharmacol 1996; 36: 580–586.
Cooney GF, Dunn SP, Kaiser B, Kulinsky AV, Mochon M, Heifets M . Oral cyclosporine pharmacokinetics in pediatric renal and liver transplant recipients. Transplant Proc 1994; 26: 2779–2780.
Dunn S . Neoral use in the pediatric transplant recipient. Transplant Proc 2000; 32 (Suppl 3A): 20–26.
Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL . Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®) in organ transplantation. Drugs 2001; 61: 1957–2016.
Caudell KA, Adams J . Cyclosporine administration practices on bone marrow transplant units: a national survey. Oncol Nurs Forum 1990; 17: 563–568.
Miller KB, Schenkein DP, Comenzo R, Erban JK, Fogaren T, Hirsch CA et al. Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 1994; 68: 15–20.
Witte T, Hoitsma A, Manoiu MM, Janssen J . Monitoring of cyclosporin during continuous intravenous administration. Bone Marrow Transplant 1986; 1: 147–150.
Kagawa Y, Sawada J, Yamada S, Matsuda H, Kageyama S, Masuya M et al. Relationship between development of nephrotoxicity and blood concentration of cyclosporine A in bone marrow transplanted recipients who received the continuous intravenous infusion. Biol Pharm Bull 2003; 26: 1115–1119.
Lindholm A . Therapeutic monitoring of cyclosporin – an update. Eur J Clin Pharmacol 1991; 41: 273–283.
Morris RG, Ilett KF, Tett SE, Ray JE, Fullinfaw RO, Cooke R et al. Cyclosporin monitoring in Australasia: 2002 update of consensus guidelines. Ther Drug Monitor 2002; 24: 677–688.
Kari T . A review of assay methods for cyclosporin. Clin Phatmacokinet 1992; 23: 173–190.
Holt DW, Johnson A . Cyclosporin A: analytic methodology and factors affecting therapeutic drug monitoring. Ther Drug Monitor 1995; 17: 625–630.
Nashan B, Bleck J, Wonigeit K, Vogt P, Christians U, Sewing KF et al. Effect of the application form of cyclosporine on blood levels: comparison of oral solution and capsules. Transplant Proc 1988; 20: 637–639.
Hilbrands LB, Hoitsma AJ, van den Berg JWO, Koene RAP . Cyclosporin A blood levels during use of cyclosporin as oral solution or in capsules: comparison of pharmacokinetic parameters. Transplant Int 1991; 4: 125–127.
Eadon H, Rose M, O'Neill R, Leaver N, Yacoub M . A pharmacokinetic comparison of cyclosporin oral solution and cyclosporin capsules in heart and lung transplant recipients. Transpl Int 1995; 8: 35–40.
Papachristou F, Gakis D, Sotiriou I, Liatsis I, Takoudas D, Antoniadis A . Pharmacokinetic study of twice vs thrice daily dosing of Sandimmun Neoral in pediatric renal transplant patients. Transplant Proc 1998; 30: 1988–1990.
Portman RJ, Meier-Kriesche HU, Swinford R, Brannan P, Kahan BD . Reduced variability of Neoral pharmacokinetic studies in pediatric renal transplantation. Pediatr Nephrol 2000; 15: 2–6.
Blifeld C, Ettenger RB . Measurement of cyclosporine levels in samples obtained from peripheral sites and indwelling lines. NEJM 1987; 317: 509.
Carreras E, Lozano M, Deulofeu R, Roman S, Granena A, Rozman C . Influence of different indwelling lines on the measurement of blood cyclosporin A levels. Bone Marrow Transplant 1988; 3: 637–639.
Busca A, Miniero R, Vassallo E, Leone L, Oddenino O, Madon E . Monitoring of cyclosporine blood levels from central venous lines: a misleading assay? Ther Drug Monitor 1994; 16: 71–74.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Choi, J., Lee, S., Chung, S. et al. Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 38, 29–35 (2006). https://doi.org/10.1038/sj.bmt.1705402
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705402
Keywords
This article is cited by
-
A decision support tool to find the best cyclosporine dose when switching from intravenous to oral route in pediatric stem cell transplant patients
European Journal of Clinical Pharmacology (2020)
-
Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals
European Journal of Clinical Pharmacology (2018)